ENALAPRIL AND QUINAPRIL PREVENT ENDOTELIAL VASODILATOR DYSFUNCTION IN RATS WITH CHRONIC NITRIC OXIDE DEFICIENCY

Bonomo S.M., 1° anno di corso del Dottorato in Farmacologia, Chemioterapia e Tossicologia Medica, XVII ciclo. Durata del dottorato in anni: 4. Sede di servizio: Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università di Milano, MILANO.

Endothelial dysfunction was investigated in male rats given N ω -nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) synthesis, in drinking water for 8 weeks. L-NAME-treated rats showed: 1) a clear-cut increase in systolic blood pressure (BP); 2) a consistent decrease of endothelial-cell NO synthase (eNOS) gene expression in aortic tissue; 3) a reduction of the relaxant activity of acetylcholine (ACh, from 10^{-10} to 10^{-4} M) on norepinephrine (NE)-precontracted aortic rings (reduction by 52 ± 5%); 4) a marked decrease (-50%) of the basal release of 6-keto-prostaglandin F1 $_{\alpha}$ (6-keto-PGF1 $_{\alpha}$) from aortic rings. In L-NAME-treated rats administration in the last 2 weeks of either the ACE-inhibitor enalapril (1 mg/kg/die) or the cognate drug quinapril (1 mg/kg/day) decreased systolic BP levels, completely restored eNOS mRNA levels in aortic tissue and allowed a consistent recovery of both the relaxant activity of ACh and the generation of 6-keto-PGF1 $_{\alpha}$. No differences was present in the ability of the two ACE-inhibitors to reverse NAME-induced endothelial dysfunction. These findings indicate that L-NAME-induced hypertension in the rats relies on the marked impairment of the endothelial cells. ACE inhibition by enalapril or quinapril was equally effective in improving endothelial vasodilator function, prostacyclin endothelial production and restoring eNOS mRNA.

SIF – Società Italiana di Farmacologia <u>http://farmacologiasif.unito.it</u>